inclusion criteria: a subject must meet all of the following criteria to be eligible to participate in this study: 1. provides written informed consent prior to initiation of any study procedures. 2. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 3. agrees to the collection of venous blood per protocol. 4. confirms to have not donated blood three months before the study 5. agrees to refrain from blood during the study and until the three months after the end of the study. 6. body mass index 18-29 kg/m2, inclusive, at screening. 7. premenopausal women must agree to use one acceptable primary form of contraception. 8. premenopausal women must have a negative urine pregnancy test the day of vaccination and are routinely using - and willing to use up to six months from vaccine administration - an effective method of birth control resulting in a low failure rate (i.e., hormonal contraception, condoms in combination with a spermicidal cream, male partner sterilization-vasectomy or total sexual abstinence). 9. oral temperature ≤37.0 degrees celsius the day of the administration of the vaccine 10. pulse no greater than 100 beats per minute. 11. systolic blood pressure (bp) is 85 to 139 mmhg, inclusive the day of vaccination. 12. should not show laboratory values outside the normal range which may have clinical significance even in absence of specific signs or symptoms.

inclusion criteria: a subject must meet all of the following criteria to be eligible to participate in this study: 1. provides written informed consent prior to initiation of any study procedures. 2. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 3. agrees to the collection of venous blood per protocol. 4. confirms to have not donated blood three months before the study 5. agrees to refrain from blood during the study and until the three months after the end of the study. 6. body mass index 18-29 kg/m2, inclusive, at screening. 7. premenopausal women must agree to use one acceptable primary form of contraception. 8. premenopausal women must have a negative urine pregnancy test the day of vaccination and are routinely using - and willing to use up to six months from vaccine administration - an effective method of birth control resulting in a low failure rate (i.e., hormonal contraception, condoms in combination with a spermicidal cream, male partner sterilization-vasectomy or total sexual abstinence). 9. oral temperature ≤37.0 degrees celsius the day of the administration of the vaccine 10. pulse no greater than 100 beats per minute. 11. systolic blood pressure (bp) is 85 to 139 mmhg, inclusive the day of vaccination. 12. should not show laboratory values outside the normal range which may have clinical significance even in absence of specific signs or symptoms.

inclusion criteria: a subject must meet all of the following criteria to be eligible to participate in this study: provides written informed consent prior to initiation of any study procedures. be able to understand and agrees to comply with planned study procedures and be available for all study visits. agrees to the collection of venous blood per protocol. confirms to have not donated blood three months before the study agrees to refrain from blood during the study and until the three months after the end of the study. body mass index 18-29 kg/m2, inclusive, at screening. premenopausal women must agree to use one acceptable primary form of contraception. premenopausal women must have a negative urine pregnancy test the day of vaccination and are routinely using - and willing to use up to six months from vaccine administration - an effective method of birth control resulting in a low failure rate (i.e., hormonal contraception, condoms in combination with a spermicidal cream, male partner sterilization-vasectomy or total sexual abstinence). oral temperature ≤37.0 degrees celsius the day of the administration of the vaccine pulse no greater than 100 beats per minute. systolic blood pressure (bp) is 85 to 139 mmhg, inclusive the day of vaccination. should not show laboratory values outside the normal range which may have clinical significance even in absence of specific signs or symptoms.

inclusion criteria: a subject must meet all of the following criteria to be eligible to participate in this study: provides written informed consent prior to initiation of any study procedures. be able to understand and agrees to comply with planned study procedures and be available for all study visits. agrees to the collection of venous blood per protocol. confirms to have not donated blood three months before the study agrees to refrain from blood during the study and until the three months after the end of the study. body mass index 18-29 kg/m2, inclusive, at screening. premenopausal women must agree to use one acceptable primary form of contraception. premenopausal women must have a negative urine pregnancy test the day of vaccination and are routinely using - and willing to use up to six months from vaccine administration - an effective method of birth control resulting in a low failure rate (i.e., hormonal contraception, condoms in combination with a spermicidal cream, male partner sterilization-vasectomy or total sexual abstinence). oral temperature ≤37.0 degrees celsius the day of the administration of the vaccine pulse no greater than 100 beats per minute. systolic blood pressure (bp) is 85 to 139 mmhg, inclusive the day of vaccination. should not show laboratory values outside the normal range which may have clinical significance even in absence of specific signs or symptoms.

inclusion criteria: a subject must meet all of the following criteria to be eligible to participate in this study: 1. provides written informed consent prior to initiation of any study procedures. 2. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 3. agrees to the collection of venous blood per protocol. 4. confirms to have not donated blood three months before the study 5. agrees to refrain from blood during the study and until the three months after the end of the study. 6. body mass index 18-29 kg/m2, inclusive, at screening. 7. premenopausal women must agree to use one acceptable primary form of contraception. 8. premenopausal women must have a negative urine pregnancy test the day of vaccination and are routinely using - and willing to use up to six months from vaccine administration - an effective method of birth control resulting in a low failure rate (i.e., hormonal contraception, condoms in combination with a spermicidal cream, male partner sterilization-vasectomy or total sexual abstinence). 9. oral temperature ≤37.0 degrees celsius the day of the administration of the vaccine 10. pulse no greater than 100 beats per minute. 11. systolic blood pressure (bp) is 85 to 139 mmhg, inclusive the day of vaccination. 12. should not show laboratory values outside the normal range which may have clinical significance even in absence of specific signs or symptoms.

inclusion criteria: a subject must meet all of the following criteria to be eligible to participate in this study: 1. provides written informed consent prior to initiation of any study procedures. 2. be able to understand and agrees to comply with planned study procedures and be available for all study visits. 3. agrees to the collection of venous blood per protocol. 4. confirms to have not donated blood three months before the study 5. agrees to refrain from blood during the study and until the three months after the end of the study. 6. body mass index 18-29 kg/m2, inclusive, at screening. 7. premenopausal women must agree to use one acceptable primary form of contraception. 8. premenopausal women must have a negative urine pregnancy test the day of vaccination and are routinely using - and willing to use up to six months from vaccine administration - an effective method of birth control resulting in a low failure rate (i.e., hormonal contraception, condoms in combination with a spermicidal cream, male partner sterilization-vasectomy or total sexual abstinence). 9. oral temperature ≤37.0 degrees celsius the day of the administration of the vaccine 10. pulse no greater than 100 beats per minute. 11. systolic blood pressure (bp) is 85 to 139 mmhg, inclusive the day of vaccination. 12. should not show laboratory values outside the normal range which may have clinical significance even in absence of specific signs or symptoms.